Trial record 1 of 1 for:    "distal hereditary motor neuropathy, type V" [DISEASE] OR "Distal Spinal Muscular Atrophy" [DISEASE] OR NCT00004568 [ID-NUMBER]
Previous Study | Return to List | Next Study

Study of Inherited Neurological Disorders

This study is currently recruiting participants. (see Contacts and Locations)
Verified January 2014 by National Institutes of Health Clinical Center (CC)
Sponsor:
Information provided by:
National Institutes of Health Clinical Center (CC)
ClinicalTrials.gov Identifier:
NCT00004568
First received: February 11, 2000
Last updated: March 14, 2014
Last verified: January 2014
  Purpose

This study is designed to learn more about the natural history of inherited neurological disorders and the role of heredity in their development. It will examine the genetics, symptoms, disease progression, treatment, and psychological and behavioral impact of diseases in the following categories: hereditary peripheral neuropathies; hereditary myopathies; muscular dystrophies; hereditary motor neuron disorders; mitochondrial myopathies; ataxias; hereditary neurocognitive disorders; inherited neurological disorders without known diagnosis; and others. Many of these diseases, which affect the brain, spinal cord, muscles, and nerves, are rare and poorly understood.

Children and adults of all ages with various inherited neurological disorders may be eligible for this study. Participants will undergo a detailed medical and family history, and a family tree will be drawn. They will also have a physical and neurological examination that may include blood test and urine tests, an EEG (brain wave recordings), psychological tests, and speech and language and rehabilitation evaluations. A blood sample or skin biopsy may be taken for genetic testing. Depending on the individual patient s symptoms, imaging tests such as X-rays, CT or MRI scans and muscle and nerve testing may also be done.

Information from this study may provide a better understanding of the genetic underpinnings of these disorders, contributing to improved diagnosis, treatment, and genetic counseling, and perhaps leading to additional studies in these areas.

...


Condition
Ataxia
Motor Neuron Disease
Muscular Disease
Muscular Dystrophy
Peripheral Nervous System Disease

Study Type: Observational
Official Title: Clinical and Molecular Manifestations of Inherited Neurological Disorders

Resource links provided by NLM:


Further study details as provided by National Institutes of Health Clinical Center (CC):

Estimated Enrollment: 2500
Study Start Date: February 2000
Detailed Description:

The Neurogenetics Branch (NGB) within the National Institute of Neurological Disorders and Stroke (NINDS) is conducting a study to evaluate and provide genetic diagnosis to participants with various diagnosed and undiagnosed neurological conditions.

OBJECTIVES:

The primary objective of this protocol is to provide a resource of patients for enrollment into new research protocols throughout the NGB and other NIH laboratories. Evaluating and diagnosing participants will allow the NGB specialists to maintain their expertise and gain additional knowledge of the course of various neurological disorders. The information obtained will allow for the evaluation and diagnosis of the studied neurological diseases. This understanding may lead to ideas for future protocols. In some cases, blood or other biologic samples (including urine, saliva, or a cheek swab) will be obtained for future laboratory studies.

STUDY POPULATION

The number of participants to be enrolled will be set to 2,000 patients with neurological diseases and their unaffected relatives.

DESIGN:

This is an observational diagnostic study of multiple neurological diseases and their progression and pathophysiology.

OUTCOME MEASURES:

No formal outcomes will be measured; however the clinical assessments of enrolled participants can be used to characterize the disease manifestations. In addition, DNA samples obtained may be used to identify and verify causative mutations as well as identify novel genes, which may help establish pathogenic mechanisms and genotype-phenotype correlations.

  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria
  • Participants include those with inherited neurological conditions based on the training and research needs of the Neurogenetics Branch program. There is no logical limit; however the total number of participants that can be enrolled in the protocol will be restricted. No more than 2,000 participants with either diagnosed or undiagnosed neurological conditions and their unaffected relatives will be enrolled in this evaluation and diagnostic protocol.

INCLUSION CRITERIA:

Participants will be eligible if they:

  • Have either a known or suspected, inherited neurological disease, OR are an unaffected relative (first-, second-, third, or higher degree relative) of a participant with a genetic neurological disease.
  • Have the ability to understand and sign an informed consent or have a parent/legal guardian to do so if they are minor children or a legal guardian to provide consent for adults without consent capacity.
  • Aged 2 years and above.

EXCLUSION CRITERIA:

Participants will not be eligible if they:

  • Are unwilling or unable to be followed as clinically indicated.
  • Have a systemic disease that compromises the ability to provide adequate neurologic examination or diagnosis.

INCLUSION CRITERIA FOR MALI:

Participants will be eligible if they:

  • Have either a known or suspected, inherited neurological disease, OR are an unaffected relative (first-, second-, third, or higher degree relative) of a participant with a genetic neurological disease.
  • Have the ability to understand and sign an informed consent or have a parent/legal guardian to do so if they are minor children or a legal guardian to provide consent for adults without consent capacity.
  • Aged 2 years and above.

EXCLUSION CRITERIA FOR MALI:

  • Participants will not be eligible if they:
  • Are unwilling or unable to be followed as clinically indicated.
  • Have a systemic disease that compromises the ability to provide adequate neurologic examination or diagnosis.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00004568

Contacts
Contact: Alice B Schindler (301) 496-8969 schindlerab@mail.nih.gov
Contact: Kenneth H Fischbeck, M.D. (301) 435-9318 kf@ninds.nih.gov

Locations
United States, Maryland
National Institutes of Health Clinical Center, 9000 Rockville Pike Recruiting
Bethesda, Maryland, United States, 20892
Contact: For more information at the NIH Clinical Center contact Patient Recruitment and Public Liaison Office (PRPL)    800-411-1222 ext TTY8664111010    prpl@mail.cc.nih.gov   
Mali
Point G Hospital Recruiting
Bamako, Mali
Sponsors and Collaborators
Investigators
Principal Investigator: Kenneth H Fischbeck, M.D. National Institute of Neurological Disorders and Stroke (NINDS)
  More Information

Additional Information:
No publications provided

ClinicalTrials.gov Identifier: NCT00004568     History of Changes
Other Study ID Numbers: 000043, 00-N-0043
Study First Received: February 11, 2000
Last Updated: March 14, 2014
Health Authority: United States: Federal Government

Keywords provided by National Institutes of Health Clinical Center (CC):
Peripheral Neuropathies
Myopathy
Muscular Dystrophy
Motor Neuron Disease
Spinocerebellar Degeneration
Neurological Disorders

Additional relevant MeSH terms:
Muscular Dystrophies
Nervous System Diseases
Motor Neuron Disease
Peripheral Nervous System Diseases
Muscular Diseases
Muscular Disorders, Atrophic
Musculoskeletal Diseases
Neuromuscular Diseases
Genetic Diseases, Inborn
Neurodegenerative Diseases

ClinicalTrials.gov processed this record on September 29, 2014